Gemcitabine + ERLOTINIB + NAB-PACLITAXEL for neoplasms, basal cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Jul 2024: Trial registered, NCT06483555
  2. 6 Feb 2025: Trial started, NCT06483555

The trials

NCT06483555: Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

State
Under way
Phase
Phase 1 and Phase 2
People
104 planned
Started
6 Feb 2025
Primary completion
Aug 2027
Arms
PurIST Basal
Results
None posted
  1. 3 Jul 2024: Trial registered
  2. 6 Feb 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.